Denied Biologic Infusion Appeals: Reviewer Outcomes

A physician-administered biologic given by infusion in the office or an infusion suite and billed under its own supply code — the medical benefit, not the pharmacy benefit. Rheumatology, gastroenterology, dermatology and neurology all sit in this group.

What the independent reviewers decided

79%

overturned by the independent reviewer

408

of 519 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny infused biologic

Step therapy: the policy requires a documented trial of one or more preferred agents first, and the record does not evidence each one.
The plan designates a different product in the class as preferred and denies the requested one as non-preferred.
The diagnosis in the record does not match an approved indication in the labelling the policy relies on.
Dosing or interval exceeds what the policy allows without additional justification.

What actually carried the cases that won

Prior treatment decided these cases almost to the exclusion of everything else. The pattern in the overturned files is a record that treats each prior agent as a discrete event — drug, dose, duration, and why it stopped, with intolerance separated from inadequate response. Reviewers leaned on peer-reviewed literature and FDA labelling more here than in any procedure group, which means the appeal that carries a labelled indication and a citation for the sequencing is arguing on the ground the reviewer already occupies.

What the record showed	Share of overturned decisions
Prior treatment was documented	91%
Conservative treatment was documented as failed	55%
The severity or urgency was documented	48%
A published guideline supported the request	42%
The condition was documented as chronic or long-standing	28%
The diagnosis was confirmed	20%
The functional impact on the patient was documented	14%
Objective findings were documented	10%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 50% of the overturned decisions
FDA labeling — in 33% of the overturned decisions
Clinical guidelines — in 27% of the overturned decisions
Specialty-society criteria — in 15% of the overturned decisions
Standard of care — in 2% of the overturned decisions

infused biologic denials — frequently asked

Is a denied biologic infusion worth appealing?

79% of 519 California independent medical reviews of infused biologics were overturned. These are disputes that had already survived the plan's own internal appeal, so the population is self-selected — but a reversal rate near four in five is a strong signal that step-therapy denials in this class do not hold up well under neutral review.

What is the single most common gap in the record?

An unevidenced step. The file says the patient failed a preferred agent but does not show the dose, the duration or the reason for stopping. Reviewers distinguish intolerance from inadequate response, and a record that blurs the two gives the plan's policy the benefit of the doubt.

Does the FDA label help?

It did in these decisions more than in most groups — FDA labelling was among the two authorities reviewers most often relied on. Where the requested indication is a labelled one, saying so plainly and pointing at the label is arguing from the source the reviewer is already reading.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →